Microfluidizer Processors for Pharmaceuticals

Microfluidizer processors enable researchers to accomplish the previously impossible, such as the development of innovative methods for targeted drug delivery using multi-functional nanomedicine.
More than 1,100 pharmaceutical companies — including 19 of the top 20 — rely on Microfluidization technology as the undisputed gold standard for uniform particle size reduction for nanoemulsions, dispersions, nanoencapsulation and cell disruption. Customers such as Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Wyeth have all published the use of our dedicated pharmaceutical homogenizers/processors to develop and produce well-known drugs and vaccines on the market today.

From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.

Proven Process Efficiency

From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.

Pharmaceutical